JRCT ID: jRCT2021210033
Registered date:07/09/2021
Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation
Basic Information
Recruitment status | Recruiting |
---|---|
Health condition(s) or Problem(s) studied | ASCVD, CKD and systemic inflammation |
Date of first enrollment | 01/09/2021 |
Target sample size | 400 |
Countries of recruitment | Argentina,Japan,Australia,Japan,Belgium,Japan,Brazil,Japan,Bulgaria,Japan,Canada,Japan,China,Japan,Denmark,Japan,Germany,Japan,Greece,Japan,India,Japan,Israel,Japan,Italy,Japan,Korea,Japan,Lithuania,Japan,Malaysia,Japan,Mexico,Japan,Netherlands,Japan,Poland,Japan,Portugal,Japan,Russian Federation,Japan,Serbia,Japan,Slovakia,Japan,South Africa,Japan,Spain,Japan,Sweden,Japan,Taiwan,Japan,Turkey,Japan,Ukraine,Japan,United Kingdom,Japan |
Study type | Interventional |
Intervention(s) | Ziltivekimab (s.c.) 15 mg once-monthly added to standard of care |
Outcome(s)
Primary Outcome | Time to first occurrence of 3-point MACE, a composite endpoint consisting of: -CV death -non-fatal MI -non-fatal stroke |
---|---|
Secondary Outcome |
Key inclusion & exclusion criteria
Age minimum | >= 20age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | Key inclusion criteria: -eGFR>=15 and < 60 mL/min/1.73 m2 (using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation) -Serum hs-CRP >=2 mg/L at screening (visit 1) -Evidence of ASCVD by one or more of the following within the last 5 years from screening: a) Coronary heart disease defined as at least one of the following: i. Documented history of MI ii. Prior coronary revascularisation procedure iii. >=50% stenosis in major epicardial coronary artery documented by cardiac catheterisation or CT coronary angiography b) Cerebrovascular disease defined as at least one of the following: i. Prior stroke of atherosclerotic origin ii. Prior carotid artery revascularisation procedure iii. >=50% stenosis in carotid artery documented by X-ray, angiography, MR angiography, CT angiography or Doppler ultrasound. c) Symptomatic peripheral artery disease (PAD) defined as at least one of the following: i. Intermittent claudication with an ankle-brachial index (ABI) <= 0.90 at rest ii. Intermittent claudication with a >=50% stenosis in peripheral artery (excluding carotid) documented by X-ray angiography, MR angiography, CT angiography or Doppler ultrasound iii. Prior peripheral artery (excluding carotid) revascularisation procedure iv. Lower extremity amputation at or above ankle due to atherosclerotic disease (excluding e.g. trauma or osteomyelitis). |
Exclude criteria | Key exclusion criteria: -Clinical evidence of, or suspicion of, active infection at the discretion of the investigator. -Myocardial infarction, stroke, hospitalisation for unstable angina pectoris, or transient ischaemic attack within 60 days prior to randomisation (visit 2). -Planned coronary, carotid or peripheral artery revascularisation known on the day of screening (visit 1). -Major cardiac surgical, non-cardiac surgical, or major endoscopic procedure (thoracoscopic or laparoscopic) within the past 60 days prior to randomisation (visit 2) or any major surgical procedure planned at the time of randomisation (visit 2). |
Related Information
Primary Sponsor | Miyazaki Daisuke |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) | NCT05021835 |
Contact
Public contact | |
Name | Daisuke Miyazaki |
Address | 2-1-1, Marunouchi, Chiyodaku, Tokyo Tokyo Japan 100-0005 |
Telephone | +81-362661000 |
JPHC_clinical_trials@novonordisk.com | |
Affiliation | Novo Nordisk Pharma Ltd. |
Scientific contact | |
Name | Daisuke Miyazaki |
Address | 2-1-1, Marunouchi, Chiyodaku, Tokyo Tokyo Japan 100-0005 |
Telephone | +81-362661000 |
JPHC_clinical_trials@novonordisk.com | |
Affiliation | Novo Nordisk Pharma Ltd. |